Related Experiment Video
Updated: Aug 14, 2025
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
8.0K
Off-time Treatment Options for Parkinson's Disease
Margherita Fabbri1, Raquel Barbosa2,3,4, Olivier Rascol2
1Department of Clinical Pharmacology and Neurosciences, Toulouse Parkinson Expert Centre, Toulouse NeuroToul Center of Excellence in Neurodegeneration (COEN), French NS-Park/F-CRIN Network, University of Toulouse 3, CHU of Toulouse, INSERM, Toulouse, France. margheritafabbrimd@gmail.com.
Neurology and Therapy
|January 12, 2023
Summary
Motor fluctuations (MF) in Parkinson's disease (PD) significantly impact quality of life. This review explores current and emerging treatments for MF, including pharmacological, device-aided, and surgical options, to manage symptoms effectively.
Area of Science:
- Neurology
- Movement Disorders
- Pharmacology
Background:
- Motor fluctuations (MF) are a primary disabling symptom in Parkinson's disease (PD), arising from fluctuating levodopa response.
- MF significantly impair patient quality of life, necessitating advanced management strategies.
Purpose of the Study:
- To provide a comprehensive overview of current and emerging therapeutic strategies for managing motor fluctuations in Parkinson's disease.
- To discuss the evolving landscape of pharmacological and advanced therapies for PD.
Main Methods:
- Narrative review of existing literature on Parkinson's disease motor fluctuations.
- Analysis of pharmacological treatments, on-demand therapies, device-aided interventions, and surgical options.
Main Results:
- The treatment landscape for MF has expanded with new oral medications, on-demand therapies, and advanced interventions like deep brain stimulation and continuous infusion systems.
- The selection of advanced therapies involves a shared decision-making process considering clinical factors, patient preferences, and healthcare system constraints.
Conclusions:
- Effective management of motor fluctuations in PD requires a personalized approach, integrating pharmacological and advanced therapies.
- Ongoing research and clinical trials are crucial for developing novel treatments and refining existing strategies for PD management.
Related Concept Videos
01:24Parkinson's Disease: Treatment
333
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
333
01:15Parkinson's Disease: Overview
645
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
645
01:22Alzheimer's Disease: Treatment
238
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
238
01:15Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
103
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
103
01:28Drug Therapy
83
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
83
01:26Psychosis: Goals of Pharmacotherapy
185
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
185